Bioceres Crop Solutions（0G4）株式概要バイオセレス・クロップ・ソリューションズ社は、その子会社とともに農作物生産性ソリューションを提供している。 詳細0G4 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より96.8%で取引されている リスク分析過去5年間で収益は年間43.2%減少しました。 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €31M )すべてのリスクチェックを見る0G4 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.3889.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-59m455m2016201920222025202620282031Revenue US$450.5mEarnings US$43.4mAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold3 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.3kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrativeBioceres Crop Solutions Corp. 競合他社DelignitSymbol: XTRA:DLXMarket cap: €28.1mEcoRubSymbol: DB:7M8Market cap: €42.2mK+SSymbol: XTRA:SDFMarket cap: €2.8bBRAIN BiotechSymbol: XTRA:BNNMarket cap: €71.0m価格と性能株価の高値、安値、推移の概要Bioceres Crop Solutions過去の株価現在の株価US$0.3852週高値US$4.3252週安値US$0.29ベータ0.391ヶ月の変化-19.07%3ヶ月変化-46.94%1年変化-89.09%3年間の変化-95.73%5年間の変化n/aIPOからの変化-96.59%最新ニュースお知らせ • May 05Bioceres Crop Solutions Corp. to Report Q3, 2026 Results on May 12, 2026Bioceres Crop Solutions Corp. announced that they will report Q3, 2026 results at 12:30 PM, US Eastern Standard Time on May 12, 2026お知らせ • Jan 12Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026. Location: 1290 avenue of the americas, ny 10104, new york United Statesお知らせ • Jan 01+ 1 more updateBioceres Crop Solutions Corp. Announces Board and Committee ChangesBioceres Crop Solutions Corp. announced changes to the composition of the board of directors of the Company. Duraiswami ("D") Narain has been appointed as a member of the Board of Directors, effective December 29, 2025. Mr. Narain has served as a non-executive director of RiceTec Inc. since 2025 and as an independent non-executive director of Medi Assist Healthcare Services Ltd. since 2024. Mr. Narain is also a founding partner of AgVaya, an organisation that collaborates with agri businesses, food companies and developmental organizations to create sustainable opportunities and drive growth in smallholder agricultural markets. Mr. Narain served as vice chairman, managing director and chief executive officer of Bayer CropScience Limited from December 2018 to October 2023, and concurrently as president at Bayer South Asia and global head of smallholder farming at Bayer. He previously served as vice president and treasurer of Monsanto Company from November 2015 to October 2018, and held various senior finance and commercial roles at Monsanto from 1998, including chief executive officer of Monsanto's India region. Mr. Narain received an MBA from the Kellogg School of Management at Northwestern University, is a chartered accountant from the Institute of Chartered Accountants of India, and holds a Bachelor of Commerce degree from the University of Madras. Mr. Narain will fill the resulting vacancy and will serve on the committees previously composed by Ms. Zang, including as chair of the audit committee.お知らせ • Oct 31Bioceres Crop Solutions Corp. announced delayed 20-F filingOn 10/30/2025, Bioceres Crop Solutions Corp. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Oct 30Bioceres Crop Solutions Corp. to Report Q1, 2026 Results on Nov 13, 2025Bioceres Crop Solutions Corp. announced that they will report Q1, 2026 results Pre-Market on Nov 13, 2025お知らせ • Oct 02Bioceres Crop Solutions Corp. Announces Resignation of Noah Kolatch as A Member of the Board of Directors, Effective September 30, 2025Bioceres Crop Solutions Corp. informs that, effective September 30, 2025, Noah Kolatch resigned as a member of the board of directors of the Company, in connection with the delivery of the reservation of rights letter delivered to the Company by Jasper Lake, through counsel, dated September 25, 2025, a copy of which is filed herewith as Exhibit 99.1. In response to the Kramer Letter, the Company delivered a reservation of rights letter to Jasper Lake on September 30, 2025, disputing that any Events of Default have occurred under the Note Purchase Agreements and reinforcing that it is in the best interest of the Company and all of its stakeholders to engage in a productive dialogue with Jasper Lake to address any legitimate concern it may have, a copy of which is filed herewith as Exhibit 99.2. The Company is committed to maintaining its focus on improving its commercial and financial performance and delivering innovative solutions to the agricultural market.最新情報をもっと見るRecent updatesお知らせ • May 05Bioceres Crop Solutions Corp. to Report Q3, 2026 Results on May 12, 2026Bioceres Crop Solutions Corp. announced that they will report Q3, 2026 results at 12:30 PM, US Eastern Standard Time on May 12, 2026お知らせ • Jan 12Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026. Location: 1290 avenue of the americas, ny 10104, new york United Statesお知らせ • Jan 01+ 1 more updateBioceres Crop Solutions Corp. Announces Board and Committee ChangesBioceres Crop Solutions Corp. announced changes to the composition of the board of directors of the Company. Duraiswami ("D") Narain has been appointed as a member of the Board of Directors, effective December 29, 2025. Mr. Narain has served as a non-executive director of RiceTec Inc. since 2025 and as an independent non-executive director of Medi Assist Healthcare Services Ltd. since 2024. Mr. Narain is also a founding partner of AgVaya, an organisation that collaborates with agri businesses, food companies and developmental organizations to create sustainable opportunities and drive growth in smallholder agricultural markets. Mr. Narain served as vice chairman, managing director and chief executive officer of Bayer CropScience Limited from December 2018 to October 2023, and concurrently as president at Bayer South Asia and global head of smallholder farming at Bayer. He previously served as vice president and treasurer of Monsanto Company from November 2015 to October 2018, and held various senior finance and commercial roles at Monsanto from 1998, including chief executive officer of Monsanto's India region. Mr. Narain received an MBA from the Kellogg School of Management at Northwestern University, is a chartered accountant from the Institute of Chartered Accountants of India, and holds a Bachelor of Commerce degree from the University of Madras. Mr. Narain will fill the resulting vacancy and will serve on the committees previously composed by Ms. Zang, including as chair of the audit committee.お知らせ • Oct 31Bioceres Crop Solutions Corp. announced delayed 20-F filingOn 10/30/2025, Bioceres Crop Solutions Corp. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • Oct 30Bioceres Crop Solutions Corp. to Report Q1, 2026 Results on Nov 13, 2025Bioceres Crop Solutions Corp. announced that they will report Q1, 2026 results Pre-Market on Nov 13, 2025お知らせ • Oct 02Bioceres Crop Solutions Corp. Announces Resignation of Noah Kolatch as A Member of the Board of Directors, Effective September 30, 2025Bioceres Crop Solutions Corp. informs that, effective September 30, 2025, Noah Kolatch resigned as a member of the board of directors of the Company, in connection with the delivery of the reservation of rights letter delivered to the Company by Jasper Lake, through counsel, dated September 25, 2025, a copy of which is filed herewith as Exhibit 99.1. In response to the Kramer Letter, the Company delivered a reservation of rights letter to Jasper Lake on September 30, 2025, disputing that any Events of Default have occurred under the Note Purchase Agreements and reinforcing that it is in the best interest of the Company and all of its stakeholders to engage in a productive dialogue with Jasper Lake to address any legitimate concern it may have, a copy of which is filed herewith as Exhibit 99.2. The Company is committed to maintaining its focus on improving its commercial and financial performance and delivering innovative solutions to the agricultural market.お知らせ • Sep 03Bioceres Crop Solutions Corp. to Report Q4, 2025 Results on Sep 09, 2025Bioceres Crop Solutions Corp. announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Sep 09, 2025お知らせ • Aug 21Bioceres Crop Solutions Corp. Announces CFO Changes, Effective from August 20, 2025Bioceres Crop Solutions Corp. announced that the board of directors (the “Board”) of the Company and Mr. Enrique Lopez Lecube, Chief Financial Officer, have agreed to initiate a transition in the Company’s financial leadership. Effective August 20, 2025, Mr. Lopez Lecube will step down from his appointment as Chief Financial Officer, and Scott Crocco, a member of the Board, will act solely to assist in managing the finance departments of the Company on an interim basis. The Company has initiated a market search for a new Chief Financial Officer. During his tenure, Mr. Lopez Lecube has made significant contributions to the Company’s financial strategy and expansion.お知らせ • Jun 20Bioceres Crop Solutions Announces Changes to Board of Directors, Effective from June 24, 2025Bioceres Crop Solutions Corp. announced changes to the composition of its Board of Directors. Noah Kolatch and Scott Crocco are being appointed to the Company's Board of Directors with effect from June 24, 2025. Noah Kolatch is a Principal at Jasper Lake LLC, a family investment office that invests across public and private markets. Prior to joining Jasper Lake, Mr. Kolatch was a Partner at Solel Partners, a Boston-based investment firm focused on public equity and credit investments. Mr. Kolatch graduated summa cum laude from Columbia College with a BA in biochemistry. Scott Crocco is a seasoned executive with over three decades of experience in finance and operations across public and private companies. Mr. Crocco was CFO of Air Products & Chemicals Inc, where he led corporate restructuring and portfolio transformation, and later served as Chief Financial Officer of Imperial Dade, a private equity-backed distributor. Mr. Crocco holds a BS in Electrical Engineering from Bucknell University and an MBA from Cornell University. Gloria Montaron Estrada, who has served as a Director since February 2019, and Keith McGovern, who has served as a Non-Executive Director since July 2022, have each resigned from the Company's Board of Directors with effect from June 24, 2025. Enrique Lopez Lecube, the Company's Chief Financial Officer and member of the Company's senior management team, will rotate off the Company's Board of Directors. The resulting vacancy will be filled by Milen Marinov, the Company's Chief Commercial Officer and member of the Company's senior management team. These changes will also be effective from June 24, 2025.お知らせ • May 10Bioceres Crop Solutions Corp. to Report Q3, 2025 Results on May 21, 2025Bioceres Crop Solutions Corp. announced that they will report Q3, 2025 results on May 21, 2025お知らせ • Mar 12Bioceres Crop Solutions and ProFarm Group's Platform, Rinotec, Receives Federal Registration from the U.S. Environmental Protection AgencyBioceres Crop Solutions and ProFarm Group announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA’s assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regions, offering growers a powerful alternative that reduces reliance on traditional chemical pesticides. These approvals highlight the product’s strong efficacy profile and position Bioceres Crop Solutions to capitalize on growing market opportunities in two of the world’s largest agricultural economies.お知らせ • Mar 06Bioceres Crop Solutions Secures Patent Protection for Hb4 Wheat in the U.S. Until 2042Bioceres Crop Solutions Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its first event-specific patent covering the HB4 Wheat, IND-OO412-7. This approval is the first of four potential patents the company is pursuing for HB4 Wheat in the United States, securing protection for this technology and associated production system until 2042. HB4 wheat offers improved tolerance to drought and enhanced weed management options compared to conventional wheat. The technology has already been approved by the USDA for cultivation and by the FDA for food and feed use in the United States. The U.S. is the fourth largest wheat producer, with nearly 40 million acres harvested in the most recent marketing year. In alignment with the company's commitment to responsible commercialization, Bioceres Crop Solutions will adhere to the U.S. Wheat Associates' (USW) "Wheat Industry Principles for Biotechnology Commercialization" developed with the National Association of Wheat Growers (NAWG). These principles include maintaining fluent dialogue with USW/NAWG, securing regulatory approvals for food and feed in major wheat export markets, establishing tolerance thresholds for low level presence, providing trait detection tests, and ensuring product stewardship through education, outreach and a certified seed value capture model. The commercial rollout of HB4 wheat in the U.S. will follow a broad licensing approach, consistent with the company's recently announced go-to-market strategy for its HB4 technology.お知らせ • Feb 06Bioceres Crop Solutions Corp. Provides Earnings Guidance for the Second Quarter Ended December 31, 2024Bioceres Crop Solutions Corp. provided earnings guidance for the second quarter ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first half of the year.お知らせ • Jan 30Bioceres Crop Solutions Corp. to Report Q2, 2025 Results on Feb 12, 2025Bioceres Crop Solutions Corp. announced that they will report Q2, 2025 results on Feb 12, 2025Reported Earnings • Nov 12First quarter 2025 earnings released: US$0.086 loss per share (vs US$0.073 loss in 1Q 2024)First quarter 2025 results: US$0.086 loss per share (further deteriorated from US$0.073 loss in 1Q 2024). Revenue: US$92.6m (down 20% from 1Q 2024). Net loss: US$5.40m (loss widened 18% from 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Oct 31Bioceres Crop Solutions Corp. to Report Q1, 2025 Results on Nov 12, 2024Bioceres Crop Solutions Corp. announced that they will report Q1, 2025 results on Nov 12, 2024お知らせ • Oct 04Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024. Location: 1290 avenue of the americas, new york, 10104, new york United StatesBuy Or Sell Opportunity • Oct 01Now 21% overvaluedOver the last 90 days, the stock has fallen 30% to €6.95. The fair value is estimated to be €5.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.6% per annum. Earnings are also forecast to grow by 36% per annum over the same time period.New Risk • Sep 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (0.7% net profit margin).Reported Earnings • Sep 11Full year 2024 earnings released: EPS: US$0.051 (vs US$0.30 in FY 2023)Full year 2024 results: EPS: US$0.051 (down from US$0.30 in FY 2023). Revenue: US$464.8m (up 11% from FY 2023). Net income: US$3.20m (down 83% from FY 2023). Profit margin: 0.7% (down from 4.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Aug 27Bioceres Crop Solutions Corp. to Report Q4, 2024 Results on Sep 10, 2024Bioceres Crop Solutions Corp. announced that they will report Q4, 2024 results on Sep 10, 2024Reported Earnings • May 14Third quarter 2024 earnings released: EPS: US$0.15 (vs US$0.45 in 3Q 2023)Third quarter 2024 results: EPS: US$0.15 (down from US$0.45 in 3Q 2023). Revenue: US$84.0m (down 9.7% from 3Q 2023). Net income: US$9.30m (down 67% from 3Q 2023). Profit margin: 11% (down from 30% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.お知らせ • May 08Bioceres Crop Solutions Corp. Announces Brazil’s Approval of New Generation Bio-InsecticideBioceres Crop Solutions Corp. announced the approval by Brazil’s Ministry of Agriculture and Livestock (MAPA- Ministério da Agricultura e Pecuária) of three new bio-insecticidal/bio-nematicidal solutions derived from inactivated cells of the company’s proprietary Burkholderia platform. The approval represents a significant regulatory milestone in the Brazilian market, marking the first endorsement of biological products formulated from fully inactivated microorganisms. Bioceres’ most advanced bio-control solutions leverage the metabolites of inactivated microorganisms, resulting in products that demonstrate heightened effectiveness, precision, shelf-life, and formulation stability, as well as greater consistency in their mode of action compared to live microbes. Moreover, non-living bacteria-based products can be formulated with increased potency and at much lower costs, nearing cost parity to less favorable present-day chemical alternatives. Bioceres products based on Burkholderia-derived metabolites were first registered in the United States in 2014 and have since been commercialized in Mexico, Peru, Chile, Turkey, and parts of Africa. In the United States alone, they are used as nematicidal and insecticidal seed treatment on more than 4 million hectares (>10 million acres) of corn, cotton and soybeans, effectively replacing abamectin in seed treatments, while also boosting the control of soil-dwelling insect pests that are typically controlled by neonicotinoids, pyrethroids, and organophosphates.お知らせ • May 03Bioceres Crop Solutions Corp. to Report Q3, 2024 Results on May 14, 2024Bioceres Crop Solutions Corp. announced that they will report Q3, 2024 results on May 14, 2024Reported Earnings • Feb 11Second quarter 2024 earnings released: EPS: US$0.002 (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.002 (up from US$0.13 loss in 2Q 2023). Revenue: US$140.3m (up 48% from 2Q 2023). Net income: US$100.0k (up US$8.26m from 2Q 2023). Profit margin: 0.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany.Board Change • Jan 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Ari Freisinger was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 26Bioceres Crop Solutions Corp. to Report Q2, 2024 Results on Feb 08, 2024Bioceres Crop Solutions Corp. announced that they will report Q2, 2024 results on Feb 08, 2024お知らせ • Nov 01+ 1 more updateBioceres Crop Solutions Corp. to Report Q1, 2024 Results on Nov 14, 2023Bioceres Crop Solutions Corp. announced that they will report Q1, 2024 results on Nov 14, 2023お知らせ • Oct 12Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023, at 10:00 US Eastern Standard Time. Location: 1290 Avenue of the Americas New York United States Agenda: To consider the report of the Board of Directors of the Company and the report of the independent auditors of the Company’s consolidated financial statements for the financial year ended June 30, 2023 and to approve the Company’s consolidated financial statements for the financial year ended June 30, 2023; to consider and vote upon a proposal to appoint the seven directors; and to consider and vote upon the ratification of appointment of Price Waterhouse & Co. S.R.L. as the independent registered public accounting firm of the Company.Reported Earnings • Sep 12Full year 2023 earnings released: EPS: US$0.26 (vs US$0.17 loss in FY 2022)Full year 2023 results: EPS: US$0.26 (up from US$0.17 loss in FY 2022). Revenue: US$419.8m (up 28% from FY 2022). Net income: US$16.7m (up US$23.9m from FY 2022). Profit margin: 4.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.お知らせ • Aug 31Bioceres Crop Solutions Corp. to Report Q4, 2023 Results on Sep 11, 2023Bioceres Crop Solutions Corp. announced that they will report Q4, 2023 results on Sep 11, 2023Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €10.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past year.Reported Earnings • May 11Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.16 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.45 (up from US$0.16 loss in 3Q 2022). Revenue: US$93.6m (up 37% from 3Q 2022). Net income: US$28.1m (up US$34.6m from 3Q 2022). Profit margin: 30% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.お知らせ • Jan 27Bioceres Crop Solutions Corp. to Report Q2, 2023 Results on Feb 09, 2023Bioceres Crop Solutions Corp. announced that they will report Q2, 2023 results on Feb 09, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Natalia Zang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 11First quarter 2023 earnings released: EPS: US$0.011 (vs US$0.021 in 1Q 2022)First quarter 2023 results: EPS: US$0.011 (down from US$0.021 in 1Q 2022). Revenue: US$127.1m (up 92% from 1Q 2022). Net income: US$498.3k (down 43% from 1Q 2022). Profit margin: 0.4% (down from 1.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.Reported Earnings • Sep 09Full year 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in FY 2021)Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.17 loss in FY 2021). Revenue: US$334.8m (up 62% from FY 2021). Net loss: US$7.33m (loss widened 6.7% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.Reported Earnings • May 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: US$69.5m (up 96% from 3Q 2021). Net loss: US$6.49m (loss widened 450% from 3Q 2021). Over the next year, revenue is forecast to grow 8.7%, compared to a 6.4% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Mar 10Now 22% undervaluedOver the last 90 days, the stock is up 4.2%. The fair value is estimated to be US$15.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last year.Board Change • Mar 05Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 11First quarter 2022 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$66.9m (up 59% from 1Q 2021). Net income: US$875.2k (up US$7.85m from 1Q 2021). Profit margin: 1.3% (up from net loss in 1Q 2021).Reported Earnings • Sep 11Full year 2021 earnings releasedThe company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$209.5m (up 22% from FY 2020). Net loss: US$6.60m (down 297% from profit in FY 2020).Board Change • Jul 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.株主還元0G4DE ChemicalsDE 市場7D-5.4%-3.9%-0.02%1Y-89.1%2.2%0.1%株主還元を見る業界別リターン: 0G4過去 1 年間で2.2 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: 0G4は、過去 1 年間で0.1 % のリターンを上げたGerman市場を下回りました。価格変動Is 0G4's price volatile compared to industry and market?0G4 volatility0G4 Average Weekly Movement20.4%Chemicals Industry Average Movement5.6%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.6%安定した株価: 0G4の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 0G4の weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001751Federico Truccoinvestors.biocerescrops.com/home/default.aspxバイオセレス・クロップ・ソリューションズ社は、子会社とともに農作物生産性ソリューションを提供している。種子・統合製品、作物保護、作物栄養の各セグメントを通じて事業を展開している。種子および統合製品部門は、より健康で高収量の作物のための種子形質、胚芽、種子処理パックを提供する。クロップ・プロテクション事業では、リゾデルマ、アジュバント、治療薬、除草剤、殺虫剤、殺菌剤、ベイト剤の開発、生産、販売を行っている。作物栄養部門は、接種剤、バイオ誘導剤、生物学的および微粒化肥料の開発、生産、商品化、販売を行っている。また、干ばつ耐性種子技術プログラムであるHB4も提供している。アルゼンチン、ブラジル、北米、欧州、中東、南米、米国、および国際的に事業を展開している。バイオセレス・クロップ・ソリューションズ社は2001年に設立され、アルゼンチンのロサリオに本社を置いている。もっと見るBioceres Crop Solutions Corp. 基礎のまとめBioceres Crop Solutions の収益と売上を時価総額と比較するとどうか。0G4 基礎統計学時価総額€26.07m収益（TTM）-€50.13m売上高(TTM)€235.61m0.1xP/Sレシオ-0.5xPER（株価収益率0G4 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0G4 損益計算書（TTM）収益US$276.60m売上原価US$172.94m売上総利益US$103.66mその他の費用US$162.52m収益-US$58.86m直近の収益報告Dec 31, 2025次回決算日May 12, 2026一株当たり利益（EPS）-0.93グロス・マージン37.48%純利益率-21.28%有利子負債／自己資本比率214.4%0G4 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 10:47終値2026/05/07 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioceres Crop Solutions Corp. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Brian Kemp DolliverBrookline Capital MarketsAustin MoellerCanaccord Genuity
Featured narrative•Materials opportunityUpside Gold3 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.3kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrative
お知らせ • May 05Bioceres Crop Solutions Corp. to Report Q3, 2026 Results on May 12, 2026Bioceres Crop Solutions Corp. announced that they will report Q3, 2026 results at 12:30 PM, US Eastern Standard Time on May 12, 2026
お知らせ • Jan 12Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026. Location: 1290 avenue of the americas, ny 10104, new york United States
お知らせ • Jan 01+ 1 more updateBioceres Crop Solutions Corp. Announces Board and Committee ChangesBioceres Crop Solutions Corp. announced changes to the composition of the board of directors of the Company. Duraiswami ("D") Narain has been appointed as a member of the Board of Directors, effective December 29, 2025. Mr. Narain has served as a non-executive director of RiceTec Inc. since 2025 and as an independent non-executive director of Medi Assist Healthcare Services Ltd. since 2024. Mr. Narain is also a founding partner of AgVaya, an organisation that collaborates with agri businesses, food companies and developmental organizations to create sustainable opportunities and drive growth in smallholder agricultural markets. Mr. Narain served as vice chairman, managing director and chief executive officer of Bayer CropScience Limited from December 2018 to October 2023, and concurrently as president at Bayer South Asia and global head of smallholder farming at Bayer. He previously served as vice president and treasurer of Monsanto Company from November 2015 to October 2018, and held various senior finance and commercial roles at Monsanto from 1998, including chief executive officer of Monsanto's India region. Mr. Narain received an MBA from the Kellogg School of Management at Northwestern University, is a chartered accountant from the Institute of Chartered Accountants of India, and holds a Bachelor of Commerce degree from the University of Madras. Mr. Narain will fill the resulting vacancy and will serve on the committees previously composed by Ms. Zang, including as chair of the audit committee.
お知らせ • Oct 31Bioceres Crop Solutions Corp. announced delayed 20-F filingOn 10/30/2025, Bioceres Crop Solutions Corp. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Oct 30Bioceres Crop Solutions Corp. to Report Q1, 2026 Results on Nov 13, 2025Bioceres Crop Solutions Corp. announced that they will report Q1, 2026 results Pre-Market on Nov 13, 2025
お知らせ • Oct 02Bioceres Crop Solutions Corp. Announces Resignation of Noah Kolatch as A Member of the Board of Directors, Effective September 30, 2025Bioceres Crop Solutions Corp. informs that, effective September 30, 2025, Noah Kolatch resigned as a member of the board of directors of the Company, in connection with the delivery of the reservation of rights letter delivered to the Company by Jasper Lake, through counsel, dated September 25, 2025, a copy of which is filed herewith as Exhibit 99.1. In response to the Kramer Letter, the Company delivered a reservation of rights letter to Jasper Lake on September 30, 2025, disputing that any Events of Default have occurred under the Note Purchase Agreements and reinforcing that it is in the best interest of the Company and all of its stakeholders to engage in a productive dialogue with Jasper Lake to address any legitimate concern it may have, a copy of which is filed herewith as Exhibit 99.2. The Company is committed to maintaining its focus on improving its commercial and financial performance and delivering innovative solutions to the agricultural market.
お知らせ • May 05Bioceres Crop Solutions Corp. to Report Q3, 2026 Results on May 12, 2026Bioceres Crop Solutions Corp. announced that they will report Q3, 2026 results at 12:30 PM, US Eastern Standard Time on May 12, 2026
お知らせ • Jan 12Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026Bioceres Crop Solutions Corp., Annual General Meeting, Jan 30, 2026. Location: 1290 avenue of the americas, ny 10104, new york United States
お知らせ • Jan 01+ 1 more updateBioceres Crop Solutions Corp. Announces Board and Committee ChangesBioceres Crop Solutions Corp. announced changes to the composition of the board of directors of the Company. Duraiswami ("D") Narain has been appointed as a member of the Board of Directors, effective December 29, 2025. Mr. Narain has served as a non-executive director of RiceTec Inc. since 2025 and as an independent non-executive director of Medi Assist Healthcare Services Ltd. since 2024. Mr. Narain is also a founding partner of AgVaya, an organisation that collaborates with agri businesses, food companies and developmental organizations to create sustainable opportunities and drive growth in smallholder agricultural markets. Mr. Narain served as vice chairman, managing director and chief executive officer of Bayer CropScience Limited from December 2018 to October 2023, and concurrently as president at Bayer South Asia and global head of smallholder farming at Bayer. He previously served as vice president and treasurer of Monsanto Company from November 2015 to October 2018, and held various senior finance and commercial roles at Monsanto from 1998, including chief executive officer of Monsanto's India region. Mr. Narain received an MBA from the Kellogg School of Management at Northwestern University, is a chartered accountant from the Institute of Chartered Accountants of India, and holds a Bachelor of Commerce degree from the University of Madras. Mr. Narain will fill the resulting vacancy and will serve on the committees previously composed by Ms. Zang, including as chair of the audit committee.
お知らせ • Oct 31Bioceres Crop Solutions Corp. announced delayed 20-F filingOn 10/30/2025, Bioceres Crop Solutions Corp. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • Oct 30Bioceres Crop Solutions Corp. to Report Q1, 2026 Results on Nov 13, 2025Bioceres Crop Solutions Corp. announced that they will report Q1, 2026 results Pre-Market on Nov 13, 2025
お知らせ • Oct 02Bioceres Crop Solutions Corp. Announces Resignation of Noah Kolatch as A Member of the Board of Directors, Effective September 30, 2025Bioceres Crop Solutions Corp. informs that, effective September 30, 2025, Noah Kolatch resigned as a member of the board of directors of the Company, in connection with the delivery of the reservation of rights letter delivered to the Company by Jasper Lake, through counsel, dated September 25, 2025, a copy of which is filed herewith as Exhibit 99.1. In response to the Kramer Letter, the Company delivered a reservation of rights letter to Jasper Lake on September 30, 2025, disputing that any Events of Default have occurred under the Note Purchase Agreements and reinforcing that it is in the best interest of the Company and all of its stakeholders to engage in a productive dialogue with Jasper Lake to address any legitimate concern it may have, a copy of which is filed herewith as Exhibit 99.2. The Company is committed to maintaining its focus on improving its commercial and financial performance and delivering innovative solutions to the agricultural market.
お知らせ • Sep 03Bioceres Crop Solutions Corp. to Report Q4, 2025 Results on Sep 09, 2025Bioceres Crop Solutions Corp. announced that they will report Q4, 2025 results at 12:30 PM, US Eastern Standard Time on Sep 09, 2025
お知らせ • Aug 21Bioceres Crop Solutions Corp. Announces CFO Changes, Effective from August 20, 2025Bioceres Crop Solutions Corp. announced that the board of directors (the “Board”) of the Company and Mr. Enrique Lopez Lecube, Chief Financial Officer, have agreed to initiate a transition in the Company’s financial leadership. Effective August 20, 2025, Mr. Lopez Lecube will step down from his appointment as Chief Financial Officer, and Scott Crocco, a member of the Board, will act solely to assist in managing the finance departments of the Company on an interim basis. The Company has initiated a market search for a new Chief Financial Officer. During his tenure, Mr. Lopez Lecube has made significant contributions to the Company’s financial strategy and expansion.
お知らせ • Jun 20Bioceres Crop Solutions Announces Changes to Board of Directors, Effective from June 24, 2025Bioceres Crop Solutions Corp. announced changes to the composition of its Board of Directors. Noah Kolatch and Scott Crocco are being appointed to the Company's Board of Directors with effect from June 24, 2025. Noah Kolatch is a Principal at Jasper Lake LLC, a family investment office that invests across public and private markets. Prior to joining Jasper Lake, Mr. Kolatch was a Partner at Solel Partners, a Boston-based investment firm focused on public equity and credit investments. Mr. Kolatch graduated summa cum laude from Columbia College with a BA in biochemistry. Scott Crocco is a seasoned executive with over three decades of experience in finance and operations across public and private companies. Mr. Crocco was CFO of Air Products & Chemicals Inc, where he led corporate restructuring and portfolio transformation, and later served as Chief Financial Officer of Imperial Dade, a private equity-backed distributor. Mr. Crocco holds a BS in Electrical Engineering from Bucknell University and an MBA from Cornell University. Gloria Montaron Estrada, who has served as a Director since February 2019, and Keith McGovern, who has served as a Non-Executive Director since July 2022, have each resigned from the Company's Board of Directors with effect from June 24, 2025. Enrique Lopez Lecube, the Company's Chief Financial Officer and member of the Company's senior management team, will rotate off the Company's Board of Directors. The resulting vacancy will be filled by Milen Marinov, the Company's Chief Commercial Officer and member of the Company's senior management team. These changes will also be effective from June 24, 2025.
お知らせ • May 10Bioceres Crop Solutions Corp. to Report Q3, 2025 Results on May 21, 2025Bioceres Crop Solutions Corp. announced that they will report Q3, 2025 results on May 21, 2025
お知らせ • Mar 12Bioceres Crop Solutions and ProFarm Group's Platform, Rinotec, Receives Federal Registration from the U.S. Environmental Protection AgencyBioceres Crop Solutions and ProFarm Group announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA’s assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regions, offering growers a powerful alternative that reduces reliance on traditional chemical pesticides. These approvals highlight the product’s strong efficacy profile and position Bioceres Crop Solutions to capitalize on growing market opportunities in two of the world’s largest agricultural economies.
お知らせ • Mar 06Bioceres Crop Solutions Secures Patent Protection for Hb4 Wheat in the U.S. Until 2042Bioceres Crop Solutions Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its first event-specific patent covering the HB4 Wheat, IND-OO412-7. This approval is the first of four potential patents the company is pursuing for HB4 Wheat in the United States, securing protection for this technology and associated production system until 2042. HB4 wheat offers improved tolerance to drought and enhanced weed management options compared to conventional wheat. The technology has already been approved by the USDA for cultivation and by the FDA for food and feed use in the United States. The U.S. is the fourth largest wheat producer, with nearly 40 million acres harvested in the most recent marketing year. In alignment with the company's commitment to responsible commercialization, Bioceres Crop Solutions will adhere to the U.S. Wheat Associates' (USW) "Wheat Industry Principles for Biotechnology Commercialization" developed with the National Association of Wheat Growers (NAWG). These principles include maintaining fluent dialogue with USW/NAWG, securing regulatory approvals for food and feed in major wheat export markets, establishing tolerance thresholds for low level presence, providing trait detection tests, and ensuring product stewardship through education, outreach and a certified seed value capture model. The commercial rollout of HB4 wheat in the U.S. will follow a broad licensing approach, consistent with the company's recently announced go-to-market strategy for its HB4 technology.
お知らせ • Feb 06Bioceres Crop Solutions Corp. Provides Earnings Guidance for the Second Quarter Ended December 31, 2024Bioceres Crop Solutions Corp. provided earnings guidance for the second quarter ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first half of the year.
お知らせ • Jan 30Bioceres Crop Solutions Corp. to Report Q2, 2025 Results on Feb 12, 2025Bioceres Crop Solutions Corp. announced that they will report Q2, 2025 results on Feb 12, 2025
Reported Earnings • Nov 12First quarter 2025 earnings released: US$0.086 loss per share (vs US$0.073 loss in 1Q 2024)First quarter 2025 results: US$0.086 loss per share (further deteriorated from US$0.073 loss in 1Q 2024). Revenue: US$92.6m (down 20% from 1Q 2024). Net loss: US$5.40m (loss widened 18% from 1Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Oct 31Bioceres Crop Solutions Corp. to Report Q1, 2025 Results on Nov 12, 2024Bioceres Crop Solutions Corp. announced that they will report Q1, 2025 results on Nov 12, 2024
お知らせ • Oct 04Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024Bioceres Crop Solutions Corp., Annual General Meeting, Oct 24, 2024. Location: 1290 avenue of the americas, new york, 10104, new york United States
Buy Or Sell Opportunity • Oct 01Now 21% overvaluedOver the last 90 days, the stock has fallen 30% to €6.95. The fair value is estimated to be €5.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.6% per annum. Earnings are also forecast to grow by 36% per annum over the same time period.
New Risk • Sep 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (0.7% net profit margin).
Reported Earnings • Sep 11Full year 2024 earnings released: EPS: US$0.051 (vs US$0.30 in FY 2023)Full year 2024 results: EPS: US$0.051 (down from US$0.30 in FY 2023). Revenue: US$464.8m (up 11% from FY 2023). Net income: US$3.20m (down 83% from FY 2023). Profit margin: 0.7% (down from 4.5% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Aug 27Bioceres Crop Solutions Corp. to Report Q4, 2024 Results on Sep 10, 2024Bioceres Crop Solutions Corp. announced that they will report Q4, 2024 results on Sep 10, 2024
Reported Earnings • May 14Third quarter 2024 earnings released: EPS: US$0.15 (vs US$0.45 in 3Q 2023)Third quarter 2024 results: EPS: US$0.15 (down from US$0.45 in 3Q 2023). Revenue: US$84.0m (down 9.7% from 3Q 2023). Net income: US$9.30m (down 67% from 3Q 2023). Profit margin: 11% (down from 30% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
お知らせ • May 08Bioceres Crop Solutions Corp. Announces Brazil’s Approval of New Generation Bio-InsecticideBioceres Crop Solutions Corp. announced the approval by Brazil’s Ministry of Agriculture and Livestock (MAPA- Ministério da Agricultura e Pecuária) of three new bio-insecticidal/bio-nematicidal solutions derived from inactivated cells of the company’s proprietary Burkholderia platform. The approval represents a significant regulatory milestone in the Brazilian market, marking the first endorsement of biological products formulated from fully inactivated microorganisms. Bioceres’ most advanced bio-control solutions leverage the metabolites of inactivated microorganisms, resulting in products that demonstrate heightened effectiveness, precision, shelf-life, and formulation stability, as well as greater consistency in their mode of action compared to live microbes. Moreover, non-living bacteria-based products can be formulated with increased potency and at much lower costs, nearing cost parity to less favorable present-day chemical alternatives. Bioceres products based on Burkholderia-derived metabolites were first registered in the United States in 2014 and have since been commercialized in Mexico, Peru, Chile, Turkey, and parts of Africa. In the United States alone, they are used as nematicidal and insecticidal seed treatment on more than 4 million hectares (>10 million acres) of corn, cotton and soybeans, effectively replacing abamectin in seed treatments, while also boosting the control of soil-dwelling insect pests that are typically controlled by neonicotinoids, pyrethroids, and organophosphates.
お知らせ • May 03Bioceres Crop Solutions Corp. to Report Q3, 2024 Results on May 14, 2024Bioceres Crop Solutions Corp. announced that they will report Q3, 2024 results on May 14, 2024
Reported Earnings • Feb 11Second quarter 2024 earnings released: EPS: US$0.002 (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.002 (up from US$0.13 loss in 2Q 2023). Revenue: US$140.3m (up 48% from 2Q 2023). Net income: US$100.0k (up US$8.26m from 2Q 2023). Profit margin: 0.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany.
Board Change • Jan 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Ari Freisinger was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 26Bioceres Crop Solutions Corp. to Report Q2, 2024 Results on Feb 08, 2024Bioceres Crop Solutions Corp. announced that they will report Q2, 2024 results on Feb 08, 2024
お知らせ • Nov 01+ 1 more updateBioceres Crop Solutions Corp. to Report Q1, 2024 Results on Nov 14, 2023Bioceres Crop Solutions Corp. announced that they will report Q1, 2024 results on Nov 14, 2023
お知らせ • Oct 12Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023Bioceres Crop Solutions Corp., Annual General Meeting, Oct 27, 2023, at 10:00 US Eastern Standard Time. Location: 1290 Avenue of the Americas New York United States Agenda: To consider the report of the Board of Directors of the Company and the report of the independent auditors of the Company’s consolidated financial statements for the financial year ended June 30, 2023 and to approve the Company’s consolidated financial statements for the financial year ended June 30, 2023; to consider and vote upon a proposal to appoint the seven directors; and to consider and vote upon the ratification of appointment of Price Waterhouse & Co. S.R.L. as the independent registered public accounting firm of the Company.
Reported Earnings • Sep 12Full year 2023 earnings released: EPS: US$0.26 (vs US$0.17 loss in FY 2022)Full year 2023 results: EPS: US$0.26 (up from US$0.17 loss in FY 2022). Revenue: US$419.8m (up 28% from FY 2022). Net income: US$16.7m (up US$23.9m from FY 2022). Profit margin: 4.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany.
お知らせ • Aug 31Bioceres Crop Solutions Corp. to Report Q4, 2023 Results on Sep 11, 2023Bioceres Crop Solutions Corp. announced that they will report Q4, 2023 results on Sep 11, 2023
Valuation Update With 7 Day Price Move • May 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €10.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past year.
Reported Earnings • May 11Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.16 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.45 (up from US$0.16 loss in 3Q 2022). Revenue: US$93.6m (up 37% from 3Q 2022). Net income: US$28.1m (up US$34.6m from 3Q 2022). Profit margin: 30% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany.
お知らせ • Jan 27Bioceres Crop Solutions Corp. to Report Q2, 2023 Results on Feb 09, 2023Bioceres Crop Solutions Corp. announced that they will report Q2, 2023 results on Feb 09, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Non-Executive Director Natalia Zang was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 11First quarter 2023 earnings released: EPS: US$0.011 (vs US$0.021 in 1Q 2022)First quarter 2023 results: EPS: US$0.011 (down from US$0.021 in 1Q 2022). Revenue: US$127.1m (up 92% from 1Q 2022). Net income: US$498.3k (down 43% from 1Q 2022). Profit margin: 0.4% (down from 1.3% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.
Reported Earnings • Sep 09Full year 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in FY 2021)Full year 2022 results: US$0.18 loss per share (further deteriorated from US$0.17 loss in FY 2021). Revenue: US$334.8m (up 62% from FY 2021). Net loss: US$7.33m (loss widened 6.7% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.
Reported Earnings • May 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: US$69.5m (up 96% from 3Q 2021). Net loss: US$6.49m (loss widened 450% from 3Q 2021). Over the next year, revenue is forecast to grow 8.7%, compared to a 6.4% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Mar 10Now 22% undervaluedOver the last 90 days, the stock is up 4.2%. The fair value is estimated to be US$15.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last year.
Board Change • Mar 05Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 11First quarter 2022 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$66.9m (up 59% from 1Q 2021). Net income: US$875.2k (up US$7.85m from 1Q 2021). Profit margin: 1.3% (up from net loss in 1Q 2021).
Reported Earnings • Sep 11Full year 2021 earnings releasedThe company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$209.5m (up 22% from FY 2020). Net loss: US$6.60m (down 297% from profit in FY 2020).
Board Change • Jul 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non Executive Director Kyle Bransfield was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
